New results from study of Oncotype DX diagnostics system in breast cancer risk- Genomic Health
Genomic Health announced new 5-year clinical outcomes results from a large PlanB study of the Oncotype DX breast cancer diagnostics system. The study, conducted by the West German Study Group, showed that 94% of early-stage breast cancer patients with Oncotype DX Recurrence Score results of 11 or less, who were treated with hormonal therapy alone, were disease-free 5 years after diagnosis. In women with Recurrence Score results of 11 or less who were treated with hormonal therapy alone, 5-year disease free survival (DFS) was estimated as 94%. Patients with Recurrence Score results of 12 to 25 who were treated with adjuvant chemotherapy also had 5-year DFS rates of 94%, while in patients with Recurrence Score results above 25 who had also received chemotherapy, 5-year DFS rates were 84%.
These new PlanB study results with 5-year outcomes provide information beyond the 3-year outcomes published recently in the Journal of Clinical Oncology. Results were announced in an oral presentation at the 10th European Breast Cancer Conference.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)